Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards
Abraxane
Pharma
BMS, BeiGene end legacy Celgene deal years after China ban
Bristol Myers will return about 23.3 million shares of BeiGene, worth about $340 million, to end the companies' partnership in China.
Angus Liu
Aug 3, 2023 10:25am
BMS unit in hot water with FDA over Abraxane production flubs
Nov 9, 2022 12:02pm
The top 10 drugs losing US exclusivity in 2022
Mar 8, 2022 3:00am
Takeda, BMS-BeiGene, Samsung and more—Fierce Pharma Asia
Oct 15, 2021 9:00am
BMS nixes BeiGene's Abraxane deal amid legal, production woes
Oct 14, 2021 10:55am
Roche pulls Tecentriq-Abraxane combo nod for breast cancer
Aug 27, 2021 2:51pm
